Hepion Pharmaceuticals, Inc. (HEPA Quick QuoteHEPA - Free Report) was a big mover last session, as the company saw its shares rise 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 38.9% in the past one-month time frame.

This move came after the company announced that it has completed human trials of the 75 mg CRV431 for the treatment of non-alcoholic steatohepatitis ("NASH") and liver disease. Also, the 225 mg CRV431 dose has been given to the first NASH patient.

The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Hepion Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

ContraVir Pharmaceuticals Inc Price

ContraVir Pharmaceuticals Inc price | ContraVir Pharmaceuticals Inc Quote

Hepion Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive/negative/0.00%.  

A better-ranked stock in the Medical - Biomedical and Genetics industry is Aerpio Pharmaceuticals, Inc. , which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot stocks we're targeting >>